Atelerix has been awarded a place on the Global Business Innovation Programme for Biomanufacturing of Biologics and Advanced Therapies in Canada. Organised by Innovate UK and delivered by Innovate UK EDGE, this programme, comprising workshops and a 5-day innovation visit to Canada, will support Atelerix’s future entry into the advanced therapies market.
“We are very pleased to be awarded a place on this programme. It will allow us to engage with advanced therapy developers in Canada to establish key pain points and confirm areas where Atelerix’s technology offers the greatest value. It will also foster key relationships, identifying collaborators and future partners, whilst gaining insight into the commercialisation and regulatory landscape in Canada.” Dr. Steve Swioklo
Atelerix sees global potential for the use of their hypothermic preservation technology in cell-based therapies and gene therapies after being demonstrated to dramatically extend the shelf life of leukapheresis starting material, therapeutic cell types, and viral vectors. The technology has also been successfully integrated into a clinical trial for an ocular cell-based therapy. It is hoped that this programme will offer an important contribution to Atelerix’s wider commercialisation within advanced therapies.
